Gonadorelin analogues (Formulary: Endocrine)

TAM (Treatments and Medicines) NHS Highland
NHS Highland

For the use of gonadorelin analogues in

  • prostate cancer see here
  • breast cancer see here 

TRIPTORELIN - (First line)

Therapy notes

  • The vial includes an overage to allow administration of the dose.

Formulation and dosage details

Formulation:

  • Powder for suspension for injection vial (Decapeptyl® SR) 3mg (Monthly injection)

Indication: 

  • Endometriosis and reduction in size of uterine fibroids, by intramuscular injection, 3mg every 4 weeks starting during first 5 days of menstrual cycle; for uterine fibroids continue treatment for at least 3 months; maximum duration of treatment 6 months (not to be repeated);

Formulation and dosage details

Formulation:

  • Powder for suspension for injection vial (Decapeptyl® SR) 11·25mg (3-monthy injection)

Indication: 

  • Endometriosis, by intramuscular injection, 11·25mg every 3 months for maximum 6 months (not to be repeated) starting during first 5 days of menstrual cycle.

Formulation and dosage details

Formulation:

  • Powder for suspension for injection vial (Decapeptyl® SR) 22·5mg (6-monthly injection) (Restricted: Specialist initiation only)

Indication: 

  • Gonadotrophin-dependent precocious puberty. 
    The treatment of children with Decapeptyl SR 22·5mg should be under the overall supervision of a Paediatric Endocrinologist, Paediatrician or Endocrinologist with expertise in the treatment of central precocious puberty.

GOSERELIN

Therapy notes

Formulation and dosage details

Formulation:

  • Implant, pre-filled disposable injection 3·6mg (Restriction: Specialist use only)

Indications: 

  • Endometriosis, by subcutaneous injection, 3·6mg every 28 days, maximum duration of treatment 6 months (do not repeat).
  • Before surgery in women who have anaemia due to uterine fibroids, 3·6mg every 28 days, maximum duration of treatment 3 months.

Editorial Information

Last reviewed: 25/05/2026

Author(s): Gynaecology, Paediatrics.

Version: 1.1

Approved By: TAM subgroup of the ADTC

Reviewer name(s): Dr S Henderson, Paediatrician.

Document Id: F193